ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival

Authors:

Abstract
Background: The ICON7 trial reported increased progression-free survival with bevacizumab (bev) added to platinum-based chemotherapy in newly-diagnosed ovarian cancer, and increased overall survival (OS) in a poor prognosis subset. Most patients (pts) had further chemotherapy following progression. On average, pts receiving bev had later progression and were thus more likely to receive further platinum. We investigated the effect of second-line treatment type on the association between first-line bev and OS.